SCHEMBL7220143

SCHEMBL7220143

Cn1cc(C(=O)O)c(=O)c2c3ccc(F)c(N4CCC(C)(C)CC4)c3ncc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
KDM4E B2RXH2 7/20 0.34
PIK3CG P48736 1/20 0.33
LMNA P02545 4/20 0.33
ADRA2B P18089 1/20 0.33
MAPK1 P28482 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HPGD P15428 4/20 0.33
HSD17B10 Q99714 4/20 0.33
KCNH2 Q12809 3/20 0.33
HRH3 Q9Y5N1 1/20 0.33
CNR2 P34972 1/20 0.33
MAPT P10636 1/20 0.33
DRD3 P35462 1/20 0.32
CHRM1 P11229 1/20 0.32
CYP1A2 P05177 1/20 0.32
TOP2A P11388 1/20 0.32
CYP2C9 P11712 1/20 0.32
TOP2B Q02880 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7219399 0.95 CNR2 (0.34) ALDH1A1KDM4EPIK3CGLMNAADRA2B
SCHEMBL7225706 0.94 KDM4E (0.34) ALDH1A1KDM4EPIK3CGLMNAADRA2B
SCHEMBL7226586 0.90 HPGD (0.39) ALDH1A1KDM4EPIK3CGLMNAADRA2B
SCHEMBL7221494 0.90 CNR2 (0.33) ALDH1A1KDM4EPIK3CGLMNAADRA2B
SCHEMBL7221681 0.89 HPGD (0.38) ALDH1A1KDM4EPIK3CGLMNAADRA2B
SCHEMBL7219230 0.88 DRD3 (0.42) ALDH1A1KDM4EPIK3CGLMNAMEN1
SCHEMBL7220551 0.88 ALDH1A1 (0.37) ALDH1A1KDM4ELMNAADRA2BMEN1
SCHEMBL7226972 0.87 LMNA (0.35) ALDH1A1KDM4EPIK3CGLMNAMEN1
SCHEMBL7227712 0.86 LMNA (0.44) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL7220070 0.85 ALDH1A1 (0.41) ALDH1A1KDM4EPIK3CGLMNAADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6566362-B2 Use as topical antibiotics AVENTIS PHARMA S.A. (FR) 2003-05-20 US disclosed
US-20020137741-A1 Benzo[f]naphthyridine derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. (FR) 2002-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137741-A1 Benzo[f]naphthyridine derivatives, their preparation and compositions containing them KCNQ2, KCNQ1, KCNQ4 ALDH1A1 719/4885KDM4E 1398/4885PIK3CG 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.